German biosimilar manufacturer STADA Arzneimittel reported a 9% revenue increase in the first half of 2024, with over €2 billion in sales, driven in part by biosimilar successes and new product launches.
German biosimilar manufacturer STADA Arzneimittel gave kudos to biosimilar successes for its increased revenues for the first half of 2024, rising 9% from the same period the year prior, according to the company’s earnings report.
STADA achieved over €2 billion (US $2.02 billion) in sales in the first half of 2024, marking a 9% increase compared with 2023, with all 3 business segments—Consumer Healthcare, Generics, and Specialty—contributing to this growth. The Specialty segment, driven by expanding biosimilars and new neurology and nephrology products, was the fastest growing and most profitable.
STADA's earnings before interest, tax, depreciation, and amortization (EBITDA) rose 11% to €463.5 million (US $511.9 million). Despite global economic challenges like inflation and stagnant growth in major economies, STADA maintained a reliable supply and adapted well to market conditions.
“STADA’s ongoing growth journey bears testimony to the strength and resilience of our 3-pillar strategy – Consumer Healthcare, Specialty and Generics. Our first-half performance ahead of the industry is a direct result of the exceptional engagement, entrepreneurial vision, and growth culture among our around 11,500 colleagues around the world,” stated Peter Goldschmidt, CEO of STADA.
Biosimilars and Specialty Medicines
In the first half of 2024, STADA's Specialty segment sales grew by 14% to €417.3 million (US $460.9 million), contributing 21% of total group revenues. The growth was driven by an expanded portfolio, including 7 biosimilars, and the roll-out of brands like Lecigon (levodopa, carbidopa monohydrate and entacapone) for Parkinson disease and Kinpeygo (budesonide) for a rare kidney disease.
Key biosimilars like Hukyndra (adalimumab), Oyavas (bevacizumab), Ximluci (ranibizumab), and Movymia (teriparatide) performed well, with Hukyndra seeing double-digit volume growth and Ximluci becoming the second-ranked biosimilar by value. STADA also launched Uzpruvo (ustekinumab) and expanded its biosimilar pipeline with partnerships for golimumab and denosumab.
Generics Success
STADA's Generics segment saw a 12% revenue increase to €838.2 million (US $925.8 million) in the first half of 2024, driven by the introduction of complex generics like rivaroxaban and dabigatran across Europe, along with strong market share growth in countries such as Germany, Italy, and Poland. STADA said this growth was supported by the generics launch pipeline covering 80% of upcoming patent expirations.
The Consumer Healthcare segment grew 3% to €768.3 million (US $848.6 million), despite a weak cough and cold season. Excluding seasonality, the segment achieved double-digit organic growth, led by strong performance in dermatology, vein health, vitamins, and disinfectants. STADA also expanded in emerging markets through partnerships in China, the Philippines, and the United Arab Emirates, contributing to overall growth in the Gulf region.
Company Culture and Performance Drivers
“Our continued growth ahead of market averages is compelling proof that our strong culture drives our performance. Across the group, we act with integrity and share best practices as One STADA, brought together by our common purpose of Caring for People’s Health as a Trusted Partner,” Goldschmidt commented.
A group-wide employee survey showed high engagement, with 89% confident in meeting business goals, and 52% of management positions held by women. STADA also ranked in the top 6% of the industry.
Reference
STADA continues strong growth journey in the first half of 2024. STADA Arzneimittel. Press release. August 28, 2024. Accessed September 9, 2024. https://www.stada.com/blog/posts/2024/august/stada-continues-strong-growth-journey-in-the-first-half-of-2024
Functional Similarity Between Ustekinumab Biosimilar ABP 654, Stelara in Crohn Disease
January 18th 2025Functional similarity of the ustekinumab biosimilar ABP 654 (Wezlana) and the reference product (Stelara) was confirmed by a series of in vitro studies, which support the totality of evidence for the biosimliar's FDA approval.
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.
Cost-Efficiency in Action: Denmark's Transition to Biosimilar Adalimumab
January 14th 2025The nationwide mandatory switch from Humira (reference adalimumab) to biosimilar adalimumab in Denmark led to no increase in total health care costs over 9 months, with significant cost reductions for those who switched to GP2017 specifically, highlighting the economic feasibility of biosimilar adoption.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Senators Introduce Bipartisan Legislation to Protect Skinny Labeling
January 2nd 2025To close out the year, 4 senators came together to introduce a new bipartisan bill to protect biosimilar and generic drug manufacturers from patent litigation when obtaining “skinny label” approvals for their products.